NHS Framework for the North of England, Branded Medicine
The NHS Commissioning Board (operating under the name of NHS England)contractFind a Tender ↗Ref ocds-h6vhtk-02e10332014L0024active
Estimated value
—
goods
Awarded value
—
Suppliers
40
4 SME
Lots
5
40 awarded
Published
01 Mar 2022
Description
HS Framework for the North of England, Branded Medicines – Tranche B, Annual Tranche and Insulin Aspart Biosimilar (Trurapi®)
Scope
- Reference
- ocds-h6vhtk-02e103
- Commercial tool
- Standalone contract
- Contract dates
- 01 Mar 2022 to 29 Feb 2024
- Main category
- goods
- CPV classifications
- 33600000
- Contract locations
- UK
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| — | — | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details· 40 awards
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
—
Award date
—
Contract start
—
Contract end
—
Awarded to
BI
IP
Lots · 5 total
Divisions of the contract. Each lot can be awarded separately.
| Lot | Title | Est. value | Status |
|---|---|---|---|
| 1 | CM/PHR/20/5600/01 - NHS Framework for the NOFE, Branded Medicines - Tranche B | — | cancelled |
| 2 | CM/PHR/20/5600/02 - NHS Framework for the NOFE, Branded Medicines-Annual Tranche | — | cancelled |
| 3 | CM/PHR/20/5600/03- NHS Framework for Insulin Aspart Biosimilar (Trurapi®)-SofE | — | cancelled |
| 4 | CM/PHR/20/5600/04-NHS Framework for Insulin Aspart Biosimilar (Trurapi®), London | — | cancelled |
| 5 | CM/PHR/20/5600/05 - NHS Framework for Insulin Aspart Biosimilar (Trurapi®), MaE | — | cancelled |